Repositioning Bazedoxifene as a novel IL-6/GP130 signaling antagonist for human rhabdomyosarcoma therapy
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Repositioning Bazedoxifene as a novel IL-6/GP130 signaling antagonist for human rhabdomyosarcoma therapy
Authors
Keywords
Rhabdomyosarcoma, Phosphorylation, Signal inhibition, STAT signaling, Cancer treatment, Angiogenesis, Apoptosis, Gene expression
Journal
PLoS One
Volume 12, Issue 7, Pages e0180297
Publisher
Public Library of Science (PLoS)
Online
2017-07-04
DOI
10.1371/journal.pone.0180297
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Inhibition of STAT3 with orally active JAK inhibitor, AZD1480, decreases tumor growth in Neuroblastoma and Pediatric Sarcomas In vitro and In vivo
- (2015) Shuang Yan et al. Oncotarget
- Drug Design Targeting Protein–Protein Interactions (PPIs) Using Multiple Ligand Simultaneous Docking (MLSD) and Drug Repositioning: Discovery of Raloxifene and Bazedoxifene as Novel Inhibitors of IL-6/GP130 Interface
- (2014) Huameng Li et al. JOURNAL OF MEDICINAL CHEMISTRY
- Cancer Incidence Rates and Trends Among Children and Adolescents in the United States, 2001-2009
- (2014) D. A. Siegel et al. PEDIATRICS
- Embryonal Rhabdomyosarcoma (Botryoid Type) of the Uterine Corpus and Cervix in Adult Women
- (2013) Rose Fanghong Li et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- A phase 2 multicentre study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma
- (2013) Peter M. Voorhees et al. BRITISH JOURNAL OF HAEMATOLOGY
- Dual Blockade of the PI3K/AKT/mTOR (AZD8055) and RAS/MEK/ERK (AZD6244) Pathways Synergistically Inhibits Rhabdomyosarcoma Cell Growth In Vitro and In Vivo
- (2013) J. Renshaw et al. CLINICAL CANCER RESEARCH
- gp130: a promising drug target for cancer therapy
- (2013) Shili Xu et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- MicroRNA-181b expression in prostate cancer tissues and its influence on the biological behavior of the prostate cancer cell line PC-3
- (2013) L. He et al. GENETICS AND MOLECULAR RESEARCH
- IL-6 expression predicts treatment response and outcome in squamous cell carcinoma of the esophagus
- (2013) Miao-Fen Chen et al. Molecular Cancer
- Discovery of a Novel Orally Active Small-Molecule gp130 Inhibitor for the Treatment of Ovarian Cancer
- (2013) S. Xu et al. MOLECULAR CANCER THERAPEUTICS
- Inhibitory Effects of a Bazedoxifene/Conjugated Equine Estrogen Combination on Human Breast Cancer Cells In Vitro
- (2012) Yan Song et al. ENDOCRINOLOGY
- Common Musculoskeletal Tumors of Childhood and Adolescence
- (2012) Carola A.S. Arndt et al. MAYO CLINIC PROCEEDINGS
- Novel small molecule, XZH-5, inhibits constitutive and interleukin-6-induced STAT3 phosphorylation in human rhabdomyosarcoma cells
- (2011) Aiguo Liu et al. CANCER SCIENCE
- IL-6 signaling in autoimmunity, chronic inflammation and inflammation-associated cancer
- (2011) Markus F. Neurath et al. CYTOKINE & GROWTH FACTOR REVIEWS
- Randomised phase II study of siltuximab (CNTO 328), an anti-IL-6 monoclonal antibody, in combination with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer
- (2011) K. Fizazi et al. EUROPEAN JOURNAL OF CANCER
- Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling
- (2011) Simon A. Jones et al. JOURNAL OF CLINICAL INVESTIGATION
- JAK1 Activates STAT3 Activity in Non-Small-Cell Lung Cancer Cells and IL-6 Neutralizing Antibodies Can Suppress JAK1-STAT3 Signaling
- (2011) L. Song et al. MOLECULAR CANCER THERAPEUTICS
- The Selective Estrogen Receptor Modulator Bazedoxifene Inhibits Hormone-Independent Breast Cancer Cell Growth and Down-Regulates Estrogen Receptor and Cyclin D1
- (2011) J. S. Lewis-Wambi et al. MOLECULAR PHARMACOLOGY
- A phase I/II study of siltuximab (CNTO 328), an anti-interleukin-6 monoclonal antibody, in metastatic renal cell cancer
- (2010) J-F Rossi et al. BRITISH JOURNAL OF CANCER
- STAT3 Activation of miR-21 and miR-181b-1 via PTEN and CYLD Are Part of the Epigenetic Switch Linking Inflammation to Cancer
- (2010) Dimitrios Iliopoulos et al. MOLECULAR CELL
- MicroRNA Expression Signature and the Role of MicroRNA-21 in the Early Phase of Acute Myocardial Infarction
- (2009) Shimin Dong et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Bazedoxifene, a selective estrogen receptor modulator
- (2009) David F. Archer et al. MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY
- The Estrogen Receptor Pathway in Rhabdomyosarcoma: A Role for Estrogen Receptor- in Proliferation and Response to the Antiestrogen 4'OH-Tamoxifen
- (2008) J. A. Greenberg et al. CANCER RESEARCH
- The Pairing of a Selective Estrogen Receptor Modulator, Bazedoxifene, with Conjugated Estrogens as a New Paradigm for the Treatment of Menopausal Symptoms and Osteoporosis Prevention
- (2008) Yogendra Kharode et al. ENDOCRINOLOGY
- Frequent in-frame somatic deletions activate gp130 in inflammatory hepatocellular tumours
- (2008) Sandra Rebouissou et al. NATURE
- The wolf in sheep's clothing: the role of interleukin-6 in immunity, inflammation and cancer
- (2008) Willscott E. Naugler et al. TRENDS IN MOLECULAR MEDICINE
- The risk of developing uterine sarcoma after tamoxifen use
- (2007) O. LAVIE et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started